Navigation Links
ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
Date:8/6/2009

EXTON, Pa., Aug. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that dosing has begun in the Phase 1 clinical trial for NTCD (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI). NTCD contains the spores of a non-toxin producing strain of C. difficile.

"Colonization of the large bowel with non-toxin producing strains of C. difficile is known to prevent the development of symptomatic CDI," commented Dr. Colin Broom, ViroPharma's chief scientific officer. "We have the opportunity with NTCD to develop this preventative therapy to significantly reduce the incidence of recurrent disease for patients with CDI. The ultimate goal is to colonize patients with this particular strain of non-toxin producing C. difficile thereby protecting patients until normal GI flora returns."

The Phase 1 study will determine the safety and tolerability of NTCD dosed orally as single and repeat escalating doses in healthy young (18-45 years of age) and older (60 years of age and older) adults. The study is being conducted in Switzerland. Should the therapy be well tolerated, the company plans to initiate NTCD repeat dosing in older adults following exposure to oral antibiotics. Antibiotic use is associated with disruption of gastrointestinal flora which renders individuals susceptible to C. difficile colonization. The goal of NTCD dosing following antibiotic exposure is to colonize with this non-toxigenic strain of C. difficile and to prevent colonization by toxigenic strains, thereby preventing disease.

"NTCD is a novel live-organism biotherapeutic approach to restoring bacterial production against CDI that has been disrupted by antibiotic treatment," state
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 The Global Allopurinol ... study on the current state of the Allopurinol ... key statistics on the state of the industry ... direction for companies and individuals interested in the ... the industry including definitions, classifications, applications and industry ...
(Date:5/29/2015)... 2015 Designed with the versatile athlete ... create an all new, exclusive line of supplementation called ... the latest and greatest, high impact, result driven ingredients ... effective. The 24/7 Series can be used by anyone ... the casual fitness enthusiasts. There are no stimulant based ...
(Date:5/29/2015)... Arlington, VA (PRWEB) May 29, 2015 ... into a new U.S. headquarters and a larger team, ... market and increase CloverETL's market share in the U.S. ... of the Javlin Group, achieved significant growth in 2014 ... sales of Javlin’s premier data integration platform, CloverETL. To ...
(Date:5/29/2015)... Texas (PRWEB) May 29, 2015 ... the current state of the Naproxen industry.The report ... definitions, classifications, applications and industry chain structure. The ... the international markets including development trends, competitive landscape ... plans are discussed as well as manufacturing processes ...
(Date:5/29/2015)... Metamora, Michigan (PRWEB) May 29, 2015 ... region and can cause significant physical, sexual, and psychological ... life altering disorder of Vulvodynia. The actual diagnosis is ... Excellence in Endometriosis, they realize that this problem can ... is experiencing any of these symptoms, they need to ...
Breaking Medicine News(10 mins):Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... for pharmacists increase the potential for medication errors, says a ... published in the May issue of the journal Medical Care. ... researchers led by College of Pharmacy professor Daniel C. Malone, ... for Education and Research on Therapeutics at the Critical Path ...
... devastating evidence of global warming keeps coming up from across ... toxic Californian// seawaters are killing marine life in their thousands. ... of days ago it was reported that a Norwegian glacier ... North Pole, a usually frozen fjord (a long narrow ...
... of couples who were interviewed at least 3 years ... their surplus, stored embryos for stem cell// research, according ... couples’ decisions, according to the authors of the report, ... through an interview process with a legal advisor and ...
... Walmex, the popular retailer in Mexico has opened the channels ... costing// as less as $3.50. This move has elevated ... to avail facilities under one roof. ,Last year, ... a similar move of providing generic drugs for $4 per ...
... and battle the disease is one thing and to realize that ... drain in health and resources may just be the last nail ... more than they can afford in Ontario hospitals to find ... are not funded by the government but are frequently prescribed by ...
... by the Canadian Cancer Society discloses that nearly 65% of ... to dangerous ultra violet rays using artificial tanning equipments. ... the WHO recommendation that children under the age of 18 ... risks. ,Skin cancer is one of the most ...
Cached Medicine News:Health News:Pharmacists' Workload Contributes To Errors 2Health News:Norwegian Glacier Shrinks and Marine Life Poisoned as the Globe Warms 2Health News:Norwegian Glacier Shrinks and Marine Life Poisoned as the Globe Warms 3Health News:Many Couples Choose to Donate Surplus Embryos for Stem Cell Research 2Health News:Cancer – Flushes Flesh and Fund 2Health News:Artificial Tanning Causes Concern 2
(Date:5/29/2015)... THOUSAND OAKS, Calif. , May 29, 2015 ... announced pooled data from two pivotal Phase 3, ... novel calcimimetic, for the treatment of secondary hyperparathyroidism ... receiving hemodialysis. Both studies met the primary endpoint, ... the AMG 416 groups achieved a greater than ...
(Date:5/28/2015)... 28, 2015 Zimmer Holdings, Inc. (NYSE and ... agreements with buyers to divest in the ... System assets, Biomet Discovery® Elbow System assets and Cobalt™ ... of Zimmer,s pending acquisition of Biomet, Inc. ("Biomet").  ... work constructively with the Bureau of Competition Staff of ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
Medicine Products: